PB2324: USE OF COMBINATION OF THALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH REFRACTORY/RELAPSED NON-HODGKIN LYMPHOMA: A PALLIATIVE CHEMOTHERAPY STRATEGY.

Παρόμοια τεκμήρια

• P1067: PHASE 2 STUDY OF ORAL THALIDOMIDE-CYCLOPHOSPHAMIDE-DEXAMETHASONE FOR RECURRENT/REFRACTORY ADULT LANGERHANS CELL HISTIOCYTOSIS
  ανά: J.-N. Wang, κ.ά.
  Έκδοση: (2022-06-01)
• PB2011: CHIDAMIDE COMBINED WITH THALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (TC2D) AS AN ORAL QUADRUPLET REGIMEN FOR RELAPSED/REFRACTORY MYELOMA PATIENTS: INITIAL RESULTS OF A PHASE IIA, MULTICENTER TRIAL
  ανά: Y. Li, κ.ά.
  Έκδοση: (2022-06-01)
• Chidamide plus prednisone, cyclophosphamide, and thalidomide for relapsed or refractory peripheral T-cell lymphoma: A multicenter phase II trial
  ανά: Jinhua Liang, κ.ά.
  Έκδοση: (2024-07-01)
• Renal pathological changes after successful treatment of LCDD using cyclophosphamide, thalidomide, and dexamethasone
  ανά: Di Wang, κ.ά.
  Έκδοση: (2021-01-01)
• Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial
  ανά: Martin Kropff, κ.ά.
  Έκδοση: (2012-05-01)